Furthermore, regorafenib, one of the main second-line drugs administered when sorafenib fails, demonstrated for the first time that its anti-tumor action in sorafenib-refractory HCC is mediated, at least in part, through FOXO3 downregulation and autophagy abolition. The gene discussed is FOXO3; the disease is neoplasm.